Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)
Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).
How this was made
The 30-second read
Why it matters
The purchase signals confidence from a major investor, likely prompting short‑term buying pressure.
Market read
First‑report insider purchase of $37M in LYCA, a material event for the micro‑cap biotech.
What to watch
Potential upcoming clinical data or financing events not disclosed in the filing.
Background
Form 4 filings disclose insider transactions; large purchases are watched for signals.
Ticker impact
Venrock Healthcare Capital Partners III purchased 2,045,440 LYCA shares for $37.7M, increasing its stake to 6,825,233 shares.
upward pressure as the market prices in insider confidence
A $37M open‑market purchase by a 10% owner is material for a micro‑cap biotech and often precedes price appreciation.
Market effects
May boost sentiment toward biotech and healthcare venture‑capital backed stocks.
Limited to U.S. biotech investors; no broader regional effect.
Low; impact confined to LYCA and similar micro‑caps.
Counterpoint
Insider buying could be a strategic stake increase unrelated to near‑term performance.
Key entities
- InvestorVenrock Healthcare Capital Partners III, L.P.
Venture capital firm acquiring a sizable stake in LYCA.
- CompanyLycia Therapeutics, Inc.
Biotech focused on rare disease therapies.
